​
​

ImmunoPrecise Antibodies (IPA) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChartTranscripts

ImmunoPrecise Antibodies Revenue Highlights

Latest Revenue (Y)

$20.66M

Latest Revenue (Q)

$6.22M

Main Segment (Y)

Project Revenue

Main Geography (Y)

UNITED STATES

ImmunoPrecise Antibodies Revenue by Period

ImmunoPrecise Antibodies Revenue by Year

DateRevenueChange
2023-04-30$20.66M6.72%
2022-04-30$19.36M8.11%
2021-04-30$17.91M27.42%
2020-04-30$14.06M28.66%
2019-04-30$10.93M100.80%
2018-04-30$5.44M106.85%
2017-04-30$2.63M38.73%
2016-04-30$1.90M7.51%
2014-12-31$1.76M100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2010-12-31-100.00%
2009-12-31-100.00%
2008-12-31-100.00%
2007-12-31-100.00%
2006-12-31-100.00%
2005-12-31-100.00%
2004-12-31-100.00%
2003-12-31-100.00%
2002-12-31--100.00%
2001-12-31$386.0016.97%
2000-12-31$330.00-95.65%
1999-12-31$7.58K-85.62%
1998-12-31$52.73K87785.00%
1997-12-31$60.00-99.08%
1996-12-31$6.53K-

ImmunoPrecise Antibodies generated $20.66M in revenue during NA 2022, up 6.72% compared to the previous quarter, and up 379.78% compared to the same period a year ago.

ImmunoPrecise Antibodies Revenue by Quarter

DateRevenueChange
2024-01-31$6.22M1.15%
2023-10-31$6.15M31.16%
2023-08-09$4.69M-16.58%
2023-04-30$5.62M8.70%
2023-01-31$5.17M-0.25%
2022-12-13$5.18M10.56%
2022-07-31$4.69M-10.50%
2022-04-30$5.24M8.81%
2022-01-31$4.82M1.97%
2021-10-31$4.72M2.92%
2021-07-31$4.59M-5.92%
2021-04-30$4.88M7.98%
2021-01-31$4.52M-5.02%
2020-10-31$4.75M26.28%
2020-07-31$3.76M-9.17%
2020-04-30$4.15M2.74%
2020-01-31$4.03M27.58%
2019-10-31$3.16M16.43%
2019-07-31$2.72M2.84%
2019-04-30$2.64M-2.02%
2019-01-31$2.70M-0.78%
2018-10-31$2.72M-5.43%
2018-07-31$2.87M58.65%
2018-04-30$1.81M5.07%
2018-01-31$1.72M30.92%
2017-10-31$1.32M122.70%
2017-07-31$591.06K-0.57%
2017-04-30$594.45K16.37%
2017-01-31$510.83K-35.97%
2016-10-31$797.81K9.68%
2016-07-31$727.42K100.00%
2016-03-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2010-09-30-100.00%
2010-03-31-100.00%
2009-09-30-100.00%
2009-06-30--100.00%
2008-09-30$131.55K636.97%
2008-06-30$17.85K-20.67%
2007-09-30$22.50K100.00%
2007-03-31-100.00%
2006-09-30-100.00%
2006-03-31--100.00%
2005-09-30$11.22K100.00%
2005-03-31--100.00%
2004-09-30$9.32K129.01%
2004-06-30$4.07K100.00%
2003-09-30-100.00%
2003-03-31-100.00%
2002-09-30-100.00%
2002-06-30-100.00%
2001-09-30--100.00%
2001-06-30$138.0013700.00%
2000-09-30$1.00-
2000-06-30$1.00-
1999-09-30$1.00-

ImmunoPrecise Antibodies generated $6.22M in revenue during Q3 2023, up 1.15% compared to the previous quarter, and up 120.00% compared to the same period a year ago.

ImmunoPrecise Antibodies Revenue Breakdown

ImmunoPrecise Antibodies Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceApr 24Apr 23Apr 22
Project Revenue$22.23M$18.68M$17.36M
Product Sales$2.04M$1.75M$1.65M

ImmunoPrecise Antibodies's latest annual revenue breakdown by segment (product or service), as of Apr 24: Project Revenue (91.62%), and Product Sales (8.38%).

ImmunoPrecise Antibodies Revenue Breakdown by Country

Annual Revenue by Country

CountryApr 24Apr 23Apr 22
Europe$10.87M$9.45M$9.43M
AUSTRALIA$482.00K$630.00K$1.54M
All Other Countries$224.00K$602.00K$1.01M
CANADA$389.00K$618.00K$572.00K
UNITED STATES$12.56M$9.37M$6.82M

ImmunoPrecise Antibodies's latest annual revenue breakdown by geography, as of Apr 24: UNITED STATES (51.21%), Europe (44.32%), AUSTRALIA (1.97%), CANADA (1.59%), and All Other Countries (0.91%).

ImmunoPrecise Antibodies Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
WVEWave Life Sciences$113.31M$19.69M
RXRXRecursion Pharmaceuticals$44.58M$14.42M
EXAIExscientia$24.96M$5.29M
TCRXTScan Therapeutics$21.05M-
IPAImmunoPrecise Antibodies$20.66M$6.22M
CUECue Biopharma$5.49M$3.34M
IPSCCentury Therapeutics$2.23M$791.00K
STTKShattuck Labs$1.66M$1.61M
TFFPTFF Pharmaceuticals$733.87K$650.22K
ANEBAnebulo Pharmaceuticals--
ZURAZura Bio--
AVTEAerovate Therapeutics--
DBTXDecibel Therapeutics--
INABIN8bio--
CGTXCognition Therapeutics--
ANNXAnnexon--
ELYMEliem Therapeutics--
DRMADermata Therapeutics--
PRDSPardes Biosciences--
UBXUnity Bio--
AVIRAtea Pharmaceuticals--
CSBRChampions Oncology--

IPA Revenue FAQ

What is ImmunoPrecise Antibodies’s yearly revenue?

ImmunoPrecise Antibodies's yearly revenue for 2022 was $20.66M, representing an increase of 6.72% compared to 2021. The company's yearly revenue for 2021 was $19.36M, representing an increase of 8.11% compared to 2020. IPA's yearly revenue for 2020 was $17.91M, representing an increase of 27.42% compared to 2019.

What is ImmunoPrecise Antibodies’s quarterly revenue?

ImmunoPrecise Antibodies's quarterly revenue for Q3 2023 was $6.22M, a 1.15% increase from the previous quarter (Q2 2023), and a 20.31% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $6.15M, a 31.16% increase from the previous quarter (Q1 2023), and a 18.63% increase year-over-year (Q2 2022). IPA's quarterly revenue for Q1 2023 was $4.69M, a -16.58% decrease from the previous quarter (Q4 2022), and a 0% increase year-over-year (Q1 2022).

What is ImmunoPrecise Antibodies’s revenue growth rate?

ImmunoPrecise Antibodies's revenue growth rate for the last 3 years (2020-2022) was 15.37%, and for the last 5 years (2018-2022) was 89.13%.

What are ImmunoPrecise Antibodies’s revenue streams?

ImmunoPrecise Antibodies's revenue streams in r 24 are Project Revenue, and Product Sales. Project Revenue generated $22.24M in revenue, accounting 91.62% of the company's total revenue, up 19.05% year-over-year. Product Sales generated $2.04M in revenue, accounting 8.38% of the company's total revenue, up 16.49% year-over-year.

What is ImmunoPrecise Antibodies’s main source of revenue?

For the fiscal year ending Apr 24, the largest source of revenue of ImmunoPrecise Antibodies was Project Revenue. This segment made a revenue of $22.24M, representing 91.62% of the company's total revenue.